Arrowhead launches Ablaris Therapeutics; Abbott, EpiTherapeutics in cancer-drug deal;

@FierceBiotech: InterMune's shares rise as CHMP backs pirfenidone. Report | Follow @FierceBiotech

 @JohnCFierce: Wonder what big pharma thinks about China's thoughts on slashing drug prices unilaterally. Emerging market or mayhem? Report | Follow @JohnCFierce

> Following a licensing deal with MD Anderson Cancer Center to obtain technology for weight loss and obesity-related metabolic conditions, Arrowhead Research Corporation says it has launched a new company, Ablaris Therapeutics, commercialize the platform. Ablaris release

> After disappointing results, Eli Lilly has suspended its late-stage melanoma trial. Tasisulam may be tested for other cancers, but will not be considered for melanoma after concerns arose from the trial data, triggering a clinical hold. Story

> Abbott Labs and EpiTherapeutics have entered a three-year deal to create cancer drugs using small-molecule inhibitors. Abbott release

> Bristol-Myers Squibb will manufacture, develop and commercialize an HIV treatment. Festinavir, a nucleoside reverse transcriptase inhibitor, is in Phase II development; the deal gives Oncolys BioPharma up to $286 million for festinavir. BMS release

And Finally... A woman who is incapable of feeling fear may help scientists discover treatments for post-traumatic stress disorder. Report

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.